Cargando…

Long-term effects of aromatase inhibitors on body mass index among postmenopausal breast cancer survivors in Africa: observational cohort study

PURPOSE: this study was conducted to assess the impact of AIs on body mass index and high sensitivity as prognostic predictors to be incorporated into point of care technology (POCT) testing in postmenopausal breast cancer women after a 24 month follow up in Africa. An observational cohort study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milambo, Jean Paul Muambangu, Nyasulu, Peter S, Akudugu, John M, Ndirangu, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012500/ https://www.ncbi.nlm.nih.gov/pubmed/36915158 http://dx.doi.org/10.1186/s13104-023-06301-6

Ejemplares similares

Feasibility of point of care testing for prevention and management of breast cancer therapy associated comorbidities in 6 African countries: short communication
por: Milambo, Jean Paul Muambngu, et al.
Publicado: (2022)

Incidence of Coronavirus Disease 2019 (COVID-19) among healthcare workers during the first and second wave in the Democratic Republic of the Congo: a descriptive study
por: Milambo, Jean Paul Muambangu, et al.
Publicado: (2023)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
por: Sendur, M A N, et al.
Publicado: (2012)

Newborn follow-up after discharge from a tertiary care hospital in the Western Cape region of South Africa: a prospective observational cohort study
por: Milambo, Jean Paul Muambangu, et al.
Publicado: (2018)

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy
por: Pedersini, Rebecca, et al.
Publicado: (2019)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Body mass index and annual increase of body mass index in long-term childhood cancer survivors; relationship to treatment
por: Brouwer, Cornelia A. J., et al.
Publicado: (2011)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study
por: Lasagna, Angioletta, et al.
Publicado: (2022)

What influences aromatase inhibitor continuation intention among breast cancer survivors?
por: Seo, Young Kyung, et al.
Publicado: (2021)

Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time
por: Shaaban, Adnan, et al.
Publicado: (2023)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Effect of Combining Impact-Aerobic and Strength Exercise, and Dietary Habits on Body Composition in Breast Cancer Survivors Treated with Aromatase Inhibitors
por: Garcia-Unciti, Marisol, et al.
Publicado: (2023)

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019)

Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
por: Bromley, Susan E., et al.
Publicado: (2019)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model
por: Arumugam, Arunkumar, et al.
Publicado: (2014)

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016)

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
por: Martino, Gabriella, et al.
Publicado: (2020)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy
por: Mayr, Barbara, et al.
Publicado: (2022)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

The relationship between tooth loss, body mass index, and hypertension in postmenopausal female
por: Mustafa Al-Ahmad, Basma Ezzat, et al.
Publicado: (2018)

Dietary Intake, Physical Activity and Body Mass Index among Postmenopausal Women
por: Ranasinghe, Chaya, et al.
Publicado: (2017)

Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer
por: Busund, Marit, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sbjgv6lljfvefdoabfetleg0lc